2-bromo-5-(4-chlorophenyl)-1,3,4-thiadiazole | 57709-58-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-5-(4-chlorophenyl)-1,3,4-thiadiazole
• CAS: 57709-58-7
• 化学式: C₈H₄BrClN₂S
• mdl: MFCD18344983
• 分子量: 275.556
• InChiKey: BCYOCBCOIDTQRC-UHFFFAOYSA-N

物化性质

• 沸点：
  371.6±44.0 °C(Predicted)
• 密度：
  1.735±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-bromo-5-(4-chlorophenyl)-1,3,4-thiadiazole 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 2-(4-chloro-phenyl)-5-hydrazino-[1,3,4]thiadiazole
  参考文献：
  名称：

  Shafiee,A. et al., Journal of Heterocyclic Chemistry, 1976, vol. 13, p. 117 - 121

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基-5-(4-氯苯基)-1,3,4-噻二唑 在 copper(ll) bromide 、 亚硝酸异戊酯 作用下， 以 乙腈 为溶剂， 生成 2-bromo-5-(4-chlorophenyl)-1,3,4-thiadiazole
  参考文献：
  名称：

  From Sphingosine Kinase to Dihydroceramide Desaturase: A Structure–Activity Relationship (SAR) Study of the Enzyme Inhibitory and Anticancer Activity of 4-((4-(4-Chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II)

  摘要：

  The sphingosine kinase (SK) inhibitor, SKI-II, has been employed extensively in biological investigations of the role of SK1 and SK2 in disease and has demonstrated impressive anticancer activity in vitro and in vivo. However, interpretations of results using this pharmacological agent are complicated by several factors: poor SK1/2 selectivity, additional activity as an inducer of SK1-degradation, and off-target effects, including its recently identified capacity to inhibit dihydroceramide desaturase-1 (Des1). In this study, we have delineated the structure-activity relationship (SAR) for these different targets and correlated them to that required for anticancer activity and determined that Des1 inhibition is primarily responsible for the antiproliferative effects of SKI-II and its analogues. In the course of these efforts, a series of novel SK1, SK2, and Des1 inhibitors have been generated, including compounds with significantly greater anticancer activity.

  DOI：

  10.1021/acs.jmedchem.5b01439

文献信息

• [EN] NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE<br/>[FR] NOUVEAUX COMPOSÉS DIAZASPIROCYCLOALCANE ET AZASPIROCYCLOALCANE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013186159A1

  公开（公告）日：2013-12-19

  The invention provides novel compounds having the general formula (I), wherein R1, R2, Y and W are as described herein, compositions including the compounds and methods of using the compounds.

  这项发明提供了具有一般公式（I）的新化合物，其中R1、R2、Y和W如本文所述，包括这些化合物的组合物以及使用这些化合物的方法。
• NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150099734A1

  公开（公告）日：2015-04-09

  The invention provides novel compounds having the general formula (I) wherein R 1 , R 2 , Y and W are as described herein, compositions including the compounds and methods of using the compounds.

  这项发明提供了具有一般化学式（I）的新化合物，其中R1、R2、Y和W如本文所述，包括该化合物的组合物以及使用该化合物的方法。
• [EN] ENZYME INTERACTING AGENTS<br/>[FR] AGENTS D'INTERACTION AVEC DES ENZYMES
  申请人：UNIV MONASH

  公开号：WO2015196258A1

  公开（公告）日：2015-12-30

  The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosure further relates to the use of such 5 compounds as research tools, use in therapy, to compositions and agents comprising said compounds, and to methods of treatment using said compounds.

  本公开涉及一般性地，但不仅限于化合物及其用作酶相互作用剂的用途，特别是与鞘脂类生物合成途径中的一个或多个酶相互作用的剂。本公开进一步涉及将这些化合物用作研究工具、治疗用途、包含所述化合物的组合物和剂，以及使用这些化合物进行治疗的方法。
• Synthesis and Pharmacological Activity of 5‐Substituted 2‐(N,N‐Dialkylaminoethyl)amino‐ and 2‐N‐Methylpiperazinyl‐1,3,4‐thiadiazoles
  作者：I. Lalezari、A. Shafiee、A. Badaly、M.M. Salimi、M.A. Khoyi、F. Abtahi、M.R. Zarrindast

  DOI：10.1002/jps.2600640732

  日期：1975.7

  corresponding 2-bromo derivatives. The reaction of the 5-substituted 2-bromo-1,3,4-thiadiazoles with N,N-dialkylaminoethylamines or N-methylpiperazine afforded the corresponding amino-1,3,4-thiadiazole derivatives. All prepared compounds displayed antihistaminic, anticholinergic, and norepinephrine-potentiating activities.

  将5-取代的2-氨基-1,3,4-噻二唑转化为其相应的2-溴衍生物。5-取代的2-溴-1,3,4-噻二唑与N，N-二烷基氨基乙胺或N-甲基哌嗪的反应得到相应的氨基-1,3,4-噻二唑衍生物。所有制备的化合物均显示出抗组胺，抗胆碱能和去甲肾上腺素增强作用。
• Diazaspirocycloalkane and azaspirocycloalkane
  申请人：Hoffmann-La Roche Inc.

  公开号：US10633384B2

  公开（公告）日：2020-04-28

  Compounds having the general formula (I) wherein R1, R2, Y and W are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.

  具有通式 (I) 的化合物 其中 R1、R2、Y 和 W 如本文所述，包括这些化合物的组合物以及将这些化合物用作自体表皮生长因子抑制剂的方法。